WHY IS THE STUDY OF THE COMPLEX SAFETY OF CELECOXIB FOR ARTHRITIS, WHICH IS CALLED PRECISION, LAST BUT NOT LEAST?
https://doi.org/10.14412/1995-4484-2017-324-326
Abstract
The paper discusses the results of the long-term PRECISION study specially designed for the prospective comparative evaluation primarily of the cardiovascular safety of celecoxib, ibuprofen, and naproxen, which are long used for the treatment of pain in patients with arthritis.
About the Author
Yu. V. Muravyev
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Муравьев ЮВ. Решает ли проблему безопасного применения НПВП усиление их селективности. В мире лекарств (клиническая фармакология и фармакотерапия). 2001;2(12):37-40 [Murav'ev YuV. Does the problem of the safe use of NSAIDs enhance the selectivity of NSAIDs? V Mire Lekarstv (Klinicheskaya Farmakologiya I Farmakoterapiya). 2001;2(12):37- 40 (In Russ.)].
2. Муравьев ЮВ. Заболевания сердечно-сосудистой системы и НПВП. Болезни сердца и сосудов. 2006;(2):52-5 [Murav'ev YuV. Diseases of the cardiovascular system and NSAIDs. Bolezni Serdtsa I Sosudov. 2006;(2):52-5 (In Russ.)].
3. Nissen SE, Yeomans ND, Solomon DH, et al; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519- 29. doi: 10.1056/NEJMoa1611593
4. Каратеев АЕ, Новикова ДС, Насонов ЕЛ. Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибито- ров циклооксигеназы 2 устарело. Научно-практическая ревматология. 2017;55(2):218-23 [Karateev AE, Novikova DS, Nasonov EL. New data on the safety of nonsteroidal anti-inflammatory drugs: the concept of the high class-specific cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):218-23 (In Russ.)]. doi: 10.14412/1995-4484- 2017-218-223
5. Grosser T, Yu Y, FitzGerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17-33. doi: 10.1146/annurev-med-011209-153129
6. Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet. 2013;382:769-79. doi: 10.1016/S0140-6736(13)60900-9
7. Couzin J. Drug testing. Massive trial of Celebrex seeks to settle safety concerns. Science. 2005;310:1890-1. doi: 10.1126/science.310.5756.1890a
8. MacDonald TM, Hawkey CJ, Ford I, et al. Randomized trial of switching from prescribed non-selective non-steroidal antiinflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur Heart J. 2016 Oct 4. pii: ehw387. doi: 10.1093/eurheartj/ehw387 [Epub ahead of print].
9. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Mar 6. pii: annrheumdis-2016- 210715. doi: 10.1136/annrheumdis-2016-210715 [Epub ahead of print].
10. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653. doi: 10.1371/journal.pone.0124653
Review
For citations:
Muravyev Yu.V. WHY IS THE STUDY OF THE COMPLEX SAFETY OF CELECOXIB FOR ARTHRITIS, WHICH IS CALLED PRECISION, LAST BUT NOT LEAST? Rheumatology Science and Practice. 2017;55(3):324-326. (In Russ.) https://doi.org/10.14412/1995-4484-2017-324-326
Views:
750
Email this article 